Welcome to our dedicated page for Organigram Global news (Ticker: OGI), a resource for investors and traders seeking the latest updates and insights on Organigram Global stock.
News about Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) focuses on its activities as a Canadian cannabis cultivator, manufacturer and brand owner operating under the Cannabis Act and Cannabis Regulations. Company announcements highlight its position as Canada’s number one cannabis company by market share in the recreational segment, as well as developments across cultivation, product innovation, beverages and international expansion.
Investors and observers following OGI news will see regular updates on quarterly and annual financial results, including net revenue trends, adjusted gross margin, adjusted EBITDA and free cash flow, as reported in its earnings releases. These updates often discuss the impact of acquisitions such as Motif Labs Ltd. and Collective Project Limited on revenue growth, extraction capabilities and beverage market participation, along with commentary on cost efficiencies and synergy realization.
Organigram’s news flow also covers product and brand launches. Examples include new SHRED gummies formats, Big Bag O’ Buds strains, BOXHOT infused pre-rolls, Trailblazer blunts, Rizzlers vapes and the happly hemp-derived THC brand in the United States. The company highlights its use of FAST™ nanoemulsion technology in ingestible products and describes how these offerings are designed around consumer preferences, including mood-based formulations.
Another important theme in Organigram news is international and policy-related activity. Releases describe record international sales, progress toward EU-GMP certification for the Moncton facility, exclusive genetics agreements with Phylos Bioscience Inc., and polling and economic reports that position legal cannabis as a contributor to Canada’s GDP, jobs and innovation. Corporate governance and leadership updates, such as CEO succession plans and executive appointments, are also communicated through news releases. For a fuller picture of OGI’s evolving strategy and operations, readers can review this ongoing stream of company disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Organigram Holdings (NASDAQ: OGI) reported strong financial results for Q2 Fiscal 2023, achieving net revenue of
Organigram Holdings Inc. (NASDAQ: OGI) announced it will report second quarter fiscal 2023 earnings results on April 11, 2023, after market close. A conference call is scheduled for April 12, 2023, at 8:00 am ET to discuss the financial outcomes. Investors will have the opportunity to register for the call in advance to receive details via email. The company, which is a leading cannabis producer in Canada, emphasized its focus on high-quality cannabis production and global partnerships. It holds a portfolio of brands catering to both recreational and medical markets.
Organigram has announced a strategic partnership with Greentank Technologies, aiming to enhance its vape market presence. The deal involves an $4 million USD investment, granting Organigram an 18-month exclusivity on new heating technology for 510 vape cartridges in Canada. This collaboration is anticipated to bolster Organigram’s product lineup, focusing on innovative heating methods that eliminate ceramic components, thus improving user experience. CEO Beena Goldenberg emphasized the commitment to innovation in the vape category, which represents approximately 17% of the Canadian market and continues to expand.
Organigram Holdings Inc. has nominated Caroline Ferland to its Board of Directors, increasing the total number of directors to ten. Ms. Ferland, a lawyer with significant international experience, previously served as BAT's Group Head of Business Conduct and Compliance, leading global compliance initiatives. She holds degrees in Economics and Law from notable Canadian universities. Peter Amirault, Board Chair, emphasized her legal and regulatory expertise as a valuable asset for the company.
Organigram operates as a licensed producer of cannabis products in Canada and aims to expand its international reach.
Organigram Holdings Inc. (NASDAQ: OGI) has received notification from Health Canada regarding its Jolts lozenge products, which were improperly classified. Initially launched in August 2021, these products are deemed cannabis extracts by the company. However, Health Canada has classified them as edibles, leading to a pause in production pending resolution. The company can still sell existing inventory until May 31, 2023. Organigram is consulting legal advisors to address the classification issue.